These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23043453)

  • 21. Advances in antiretroviral therapy.
    Arribas JR; Eron J
    Curr Opin HIV AIDS; 2013 Jul; 8(4):341-9. PubMed ID: 23666392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study.
    Negredo E; Paredes R; Peraire J; Pedrol E; Côté H; Gel S; Fumoz CR; Ruiz L; Abril V; Rodriguez de Castro E; Ochoa C; Martinez-Picado J; Montaner J; Rey-Joly C; Clotet B;
    Antivir Ther; 2004 Dec; 9(6):889-93. PubMed ID: 15651747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
    Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
    J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initiating therapy: when to start, what to use.
    Hirsch MS
    J Infect Dis; 2008 May; 197 Suppl 3():S252-60. PubMed ID: 18447611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).
    Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME
    Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.
    Burgos J; Crespo M; Falcó V; Curran A; Navarro J; Imaz A; Domingo P; Podzamczer D; Mateo MG; Villar S; Van den Eynde E; Ribera E; Pahissa A
    J Antimicrob Chemother; 2012 Oct; 67(10):2479-86. PubMed ID: 22729925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging antiretroviral drugs.
    Fernández-Montero JV; Vispo E; Soriano V
    Expert Opin Pharmacother; 2014 Feb; 15(2):211-9. PubMed ID: 24289800
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Jungmann NA; Lang D; Saleh S; Van Der Mey D; Gerisch M
    Expert Opin Drug Metab Toxicol; 2019 Nov; 15(11):975-984. PubMed ID: 31619082
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States.
    Sweet DE; Altice FL; Cohen CJ; Vandewalle B
    PLoS One; 2016; 11(1):e0147821. PubMed ID: 26808503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The quad pill, a once-daily combination therapy for HIV infection.
    Johnson LB; Saravolatz LD
    Clin Infect Dis; 2014 Jan; 58(1):93-8. PubMed ID: 24065329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-Tablet Regimens for the Treatment of HIV-1 Infection.
    Sebaaly JC; Kelley D
    Ann Pharmacother; 2017 Apr; 51(4):332-344. PubMed ID: 27895236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Doravirine: a review.
    Colombier MA; Molina JM
    Curr Opin HIV AIDS; 2018 Jul; 13(4):308-314. PubMed ID: 29794817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-daily therapies for the treatment of HIV infection.
    Tashima KT; Mitty JA
    Curr HIV/AIDS Rep; 2006 Jul; 3(2):86-92. PubMed ID: 16608665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerability is more important than simplicity for treatment durability.
    Trottier B; Machouf N; Huchet E; Lavoie S; Vezina S; Boissonnault M; Charest L; Munoz M; Legault D; Longpré D; Thomas R
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19765. PubMed ID: 25397509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV Clinical Updates: New Single-Tablet Regimens.
    Sebaaly JC; Kelley D
    Ann Pharmacother; 2019 Jan; 53(1):82-94. PubMed ID: 30073873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. When food can make the difference: The case of elvitegravir-based co-formulation.
    Cattaneo D; Baldelli S; Minisci D; Meraviglia P; Clementi E; Galli M; Gervasoni C
    Int J Pharm; 2016 Oct; 512(1):301-304. PubMed ID: 27592195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components.
    Llibre JM; de Lazzari E; Molina JM; Gallien S; Gonzalez-García J; Imaz A; Podzamczer D; Clotet B; Domingo P; Gatell JM
    Enferm Infecc Microbiol Clin (Engl Ed); 2018 Jan; 36(1):16-20. PubMed ID: 27595183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dolutegravir/rilpivirine for the treatment of HIV-1 infection.
    Dowers E; Zamora F; Barakat LA; Ogbuagu O
    HIV AIDS (Auckl); 2018; 10():215-224. PubMed ID: 30464642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV treatment 2020: what will it look like?
    Gulick R
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19528. PubMed ID: 25394037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.